134575-06-7Relevant articles and documents
Development of multikilogram continuous flow cyclopropanation of N -benzylmaleimide through kinetic analysis
Buono, Frederic G.,Eriksson, Magnus C.,Yang, Bing-Shiou,Kapadia, Suresh R.,Lee, Heewon,Brazzillo, Jason,Lorenz, Jon C.,Nummy, Laurence,Busacca, Carl A.,Yee, Nathan,Senanayake, Chris
, p. 1527 - 1534 (2014)
A convenient and high-yielding method for the synthesis of trans-(dioxo)-azabicyclo-[3.1.0]-hexane carboxylate, a key intermediate of complex molecules, is presented using a flow cyclopropanation process. From a detailed kinetic study, it is demonstrated that the reaction concentration, addition time of reagents, and initial mixing temperature are the critical parameters to minimize formation of byproducts and to get high reaction yield. Using a modular tubular flow reactor, the trans/cis-(dioxo)-azabicyclo-[3.1.0]-hexane carboxylate was obtained in 92% yield and isomerized under basic conditions to produce the trans-isomer in greater than 99% diastereomeric excess. Using this approach, the reaction yield was significantly increased compared to the batch process, and the robustness and reproducibility of this flow process was demonstrated for the synthesis of this key intermediate on a multikilogram scale.
Synthesis and structure-activity relationship of N-(3-azabicyclo[3.1.0]hex- 6-ylmethyl)-5-(2-pyridinyl)-1,3-thiazol-2-amines derivatives as NPY Y5 antagonists
Biagetti, Matteo,Leslie, Colin Philip,Mazzali, Angelica,Seri, Catia,Pizzi, Domenica Antonia,Bentley, Jonathan,Genski, Thorsten,Fabio, Romano Di,Zonzini, Laura,Caberlotto, Laura
scheme or table, p. 4741 - 4744 (2010/10/04)
A novel class of small molecule NPY Y5 antagonists based around an azabicyclo[3.1.0]hexane scaffold was identified through modification of a screening hit. Structure-activity relationships and efforts undertaken to achieve a favourable pharmacokinetic profile in rat are described.
3-(Imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers: A novel series of mGluR2 positive allosteric modulators
Zhang, Lei,Rogers, Bruce N.,Duplantier, Allen J.,McHardy, Stanley F.,Efremov, Ivan,Berke, Helen,Qian, Weimin,Zhang, Andy Q.,Maklad, Noha,Candler, John,Doran, Angela C.,Lazzaro Jr., John T.,Ganong, Alan H.
scheme or table, p. 5493 - 5496 (2009/06/18)
The synthesis and structure-activity relationship (SAR) of a novel series of 3-(imidazolyl methyl)-3-aza-bicyclo[3.1.0]hexan-6-yl)methyl ethers, derived from a high throughput screening (HTS), are described. Subsequent optimization led to identification of potent, metabolically stable and orally available mGluR2 positive allosteric modulators (PAMs).
A new method for the synthesis of ethyl (1α, 5α, 6α)-3-benzyl-3-azabicyclo[3.1.0.]hexane-2,4-dione-6-carboxylate: An intermediate for the trovafloxacin side chain
Agrawal,Srivastava, Stuti,Singh, Vishnu S.,Dikshit, Dinesh K.,Bose, Prosenjit,Sharma, Pankaj,Kumar, Naresh
, p. 873 - 875 (2007/10/03)
A convenient and high yield process for ethyl (1α, 5α, 6α)-3-benzyl-3-azabicyclo [3.1.0.]hexane-2,4-dione-6-carboxylate using a facile endo-exo conversion by DBU is described.
Synthesis of new fluoroquinolones and evaluation of their in vitro activity on Toxoplasma gondii and Plasmodium spp.
Anquetin,Rouquayrol,Mahmoudi,Santillana-Hayat,Gozalbes,Greiner,Farhati,Derouin,Guedj,Vierling
, p. 2773 - 2776 (2007/10/03)
The synthesis of four new computer-designed fluoroquinolones which have been predicted by QSAR analysis to be active against the protozoa Toxoplasma gondii is described. These compounds are inhibitory in vitro for T. gondii. One of these compounds has a remarkably high activity comparable to that of trovafloxacin. It combines the basic cyclopropyl-quinoline structure of gatifloxacin or moxifloxacin with the C-7 6-amino-3-azabicyclo[3.1.0]hexyl side chain of trovafloxacin. The four compounds are also inhibitory for blood stages of Plasmodium falciparum though at high concentration. These results confirm the potential of quinolones as anti-T. gondii and antimalarial drugs but also show that the QSAR models for T. gondii cannot be reliably extended for screening antimalarial activity.
Azabicyclo quinolone carboxylic acids
-
, (2008/06/13)
Quinolone carboxylic acids 7-substituted by azabicyclo groups have antibacterial activity., Antibacterial wherein, R1 is hydrogen, a pharmaceutically acceptable cation, or alkyl;, Y, when taken independently, is ethyl, t-butyl, vinyl, cyclopropyl, 2-fluoroethyl, p-fluorophenyl, or o,p-difluorophenyl;, W is hydrogen, F, Cl, Br, alkyl, alkoxy, NH2, NHCH3;, A is CH, CF, CCl, COCH3, C-CH3, C-CN or N; or, A is carbon and is taken together with Y and the carbon and nitrogen to which A and Y are attached to form a five or six membered ring which may contain oxygen or a double bond, and which may have attached thereto R8 which is methyl or methylene; and, R2 is wherein R3, R4, R5, R6, R7, R9, R10 and R25 are each independently H, CH3, CH2NH2, CH2NHCH3 or CH2NHC2H5, and R5, R6, R7, and R9 may also independently be NH2, NHCH3 or NHC2H5.